This paper discusses the current evidence from animal and human studies for a central role of inflammation in schizophrenia. In animal models, pre-or perinatal elicitation of the immune response may increase immune reactivity throughout life, and similar findings have been described in humans. Levels of pro-inflammatory markers, such as cytokines, have been found to be increased in the blood and cerebrospinal fluid of patients with schizophrenia. Numerous epidemiological and clinical studies have provided evidence that various infectious agents are risk factors for schizophrenia and other psychoses. For example, a large-scale epidemiological study performed in Denmark clearly showed that severe infections and autoimmune disorders are such risk factors. The vulnerability-stress-inflammation model may help to explain the role of inflammation in schizophrenia because stress can increase pro-inflammatory cytokines and may even contribute to a chronic pro-inflammatory state. Schizophrenia is characterized by risk genes that promote inflammation and by environmental stress factors and alterations of the immune system. Typical alterations of dopaminergic, serotonergic, noradrenergic, and glutamatergic neurotransmission described in schizophrenia have also been found in low-level neuroinflammation and consequently may be key factors in the generation of schizophrenia symptoms. Further support for the relevance of a low-level neuroinflammatory process in schizophrenia is provided by the loss of central nervous system volume and microglial activation demonstrated in neuroimaging studies. Last but not least, the benefit of anti-inflammatory medications found in some studies and the intrinsic anti-inflammatory and immunomodulatory effects of antipsychotics provide further support for the role of inflammation in this debilitating disease.
Introduction
Inflammation is a necessary response to infection, harmful chemicals, and tissue damage. 1 In addition to protecting the body, however, it may have harmful effects, as seen in infectious and autoimmune diseases, eg, multiple sclerosis (MS) . The contrasting effects of inflammation are also seen in the central nervous system (CNS), where it may be neuroprotective or neurotoxic. 2 Whether the inflammation response has positive or negative effects depends on interactions between environmental factors and various components of the inflammatory response, whereby genetic variation plays an important role in the latter.
The negative effects of inflammation also depend on whether the inflammatory state is acute or chronic. Acute encephalitis in the CNS, eg, can be potentially fatal within a matter of hours or days, whereas chronic inflammation in the CNS may have negative effects for months or years and even over the course of a lifetime. MS is another example of an inflammatory disease that can be both acute, with relapses interspersed with periods of remission, or chronic and progressive. Both the acute and chronic manifestations of MS are purported to be a result of inflammation in the CNS, 3 in the sense of a "smoldering inflammation." The inflammatory mechanisms are hypothesized to differ in the acute and chronic stages, whereas the peripheral immune system is proposed to be closely involved in the acute stage in that macrophages and B-and T-cells invade the CNS, it is thought not to play a role in the chronic phase, in which a local immune response in the CNS is at play that is separate from the peripheral immune system ("compartmentalization" of the inflammatory process). 4, 5 This hypothesis is supported by the fact that disseminated activation of microglial cells (which arise partly from the yolk sac and partly reside in the brain as macrophages) is the primary characteristic of chronic MS.
Because MS is a disease of the CNS and can have a waxing and waning or chronic course, claims have often been made that the pathogenetic mechanisms of MS may be similar to those of schizophrenia. 7 Schizophrenia has often been described to be associated with chronic inflammation in the CNS. 8 Symptoms of schizophrenia have been described in several inflammatory diseases, eg, in the encephalitic form of MS 9 ; in viral infections of the CNS, eg, herpes simplex virus type 1 (HSV-1), 10 HSV-2, 11 and measles
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; and in autoimmune diseases, eg, poststreptococcal disorders, [13] [14] [15] [16] and system lupus erythematosus and scleroderma. [17] [18] [19] However, inflammatory mechanisms differ between MS and schizophrenia, eg, because typical centers of inflammation are not found in schizophrenia. Possible mechanisms of inflammation in schizophrenia are discussed below.
Inflammation in the CNS
Pro-inflammatory cytokines, microglia, astrocytes, and immune cells of the peripheral immune system, including monocytes, macrophages, and T-and B-lymphocytes, are all involved in mediating inflammation in the CNS. As mentioned above, the inflammatory response is an essential process if well regulated but can harm rather than help host cells if excessive. Dysregulation of the inflammatory response can have various causes, including infectious agents, such as bacteria and viruses, and environmental toxins. It may also be a secondary reaction to trauma-related neuronal lesions or be a genetic effect.
The Role of Microglia
Microglia are the most important component of the local CNS immune system and constitute between 10% and 20% of all cells in the CNS. 20 They play the main role in neuroinflammation and provide the first line of defense in case of injury or disease. They are activated if the body is exposed to a systemic infection, eg, and are involved in the synthesis of the central, pro-inflammatory cytokines that are released in case of such an infection and result in a variety of mental states, including "sickness behavior." 21 Reports of higher levels of pro-inflammatory cytokines and lower levels of anti-inflammatory cytokines in schizophrenia are discussed below. Positron emission tomography (PET) studies showing microglia activation are also mentioned, although the results of these studies are somewhat inconsistent.
As a caveat, it has to be mentioned that the dualism of pro-and anti-inflammatory cytokines is a simplification because certain cytokines can have both pro-and anti-inflammatory properties, depending on several factors, including dose. 22 Further discussion of this topic, however, is beyond the scope of this overview.
Besides the acute activation of microglia, a variety of low-level stimuli can cause them to be "sensitized" or "primed," 23 a process that elicits an exaggerated immune response. Examples of such stimuli are the ageing process, 24 neurodegeneration, 25 and stress. 26 Once microglia are primed, an additional low-level stimulus, eg, minor systemic inflammation, may cause them to proliferate and increase production of pro-inflammatory cytokines, 27 which in turn may exacerbate or re-exacerbate an immune response in the CNS and be visible as an acute change in behavior. 28 
Stress-induced Inflammation in Psychiatric Disorders:
The Role of Kindling/Sensitization "Kindling," also referred to as "sensitization," is a process by which an initial immune response to a stimulus, eg, stress or infection, strengthens or lowers the threshold for a response to future exposure to the same stimulus, ie, a weaker stimulus is required to activate the immune response or cytokine release is greater than at the initial exposure. A memory function of the acquired immune system is hypothesized to be responsible for this process. 26, 29 For example, in rats, release of IL-6 in response to stress was found to reactivate (prenatally) conditioned processes. 30 Exposure of healthy people to an additional stimulus, such as systemic inflammation or stress, results in activation of the immune response, including cell proliferation and increased production and release of pro-inflammatory cytokines. 27 Kindling may also provide support to the hypothesis that infection in early childhood can result in increased release of cytokines upon activation of the immune system by reinfection or another stimulus later in life, resulting in neurotransmitter disturbances.
Kindling plays a key role in immune activation. Psychopathological symptoms and inflammation are associated with the immune response to stress, and inflammation is also involved in stress-related changes in behavior induced by cytokines and mediated by neurotransmitters. Stress evokes a pro-inflammatory immune response, which normally is downregulated after the stressful event. It has been shown in experiments that after chronic stress or repeated stressful events, the threshold for the physiological reactions to stress is downregulated and a smaller stimulus suffices to trigger an immune or a neurotransmitter response. For example, one animal study showed that the aged brain is in a proinflammatory, sensitized state and shows a greater cytokine response to inflammatory stimuli than the brains of younger animals. 26 In other animal studies, re-exposure to a cytokine resulted in greater neurotransmitter responses, 31 as shown for example with TNF-α. 32 In the CNS, stress may cause activation and proliferation of microglia, which in turn may mediate these cytokine effects. 33 Kindling is at least partly due to the memory function of the acquired immune system. 26, 29 Stress-associated release of pro-inflammatory cytokines is hypothesized to reactivate conditioned processes, 30 acting as a "second hit."
The Vulnerability-stress-inflammation Model of Schizophrenia
Forty years ago, Zubin and Spring 34 first proposed the vulnerability-stress model of schizophrenia. This model proposes that stress, whether physical or mental, can trigger a psychotic episode. Today, this model has to be expanded to become the vulnerability-stress-inflammation model because inflammation is known to play a role in schizophrenia and can be induced by stress. For example, if an inflammatory response is stimulated in mothers in the second trimester or in the offspring while the CNS is still developing, the offspring have greater vulnerability for schizophrenia. Studies in animals have shown that stress leads to increased levels of pro-inflammatory cytokines. 26 Genetic makeup also contributes to the level of vulnerability to stress, as described in the pathogen-host defense hypothesis. 35 Markers of inflammation and the effects of inflammation on neurotransmitter systems in schizophrenia are described in detail below (see Figure 1 ).
Markers of Inflammation
Only a few of the studies on markers of inflammation can be discussed here because of space limitations. Such studies have found degradation products of fibrin, a protein that is increased in inflammatory processes, in brains of schizophrenia patients' postmortem 36 and in the cerebrospinal fluid (CSF) of about 50% of patients with schizophrenia. 37 Furthermore, several studies have observed a blunted type 1 and an increased type 2 cytokine pattern in untreated patients with schizophrenia. 38 A meta-analysis of cytokines in schizophrenia found higher levels of proinflammatory cytokines in the peripheral blood in both patients with first-episode schizophrenia and relapsed patients than in healthy controls, but it also found higher levels of some anti-inflammatory cytokines in these patients than in controls. 39 A meta-analysis of cytokines in the CSF showed similar results, ie, higher levels of proinflammatory and lower levels of anti-inflammatory cytokines. 40 A critical discussion of these findings has to consider confounding factors, such as smoking, body mass index, gender, sleep, medication, etc. Moreover, several cytokines act primarily in a paracrine way, and blood levels of these cytokines may not appropriately reflect their function. A general discussion has to mention that the brain is protected from peripheral inflammation by the blood-brain barrier and that an immune activation, including an increase in pro-inflammatory cytokines in the blood, does not reflect the situation in the brain. 41 Nevertheless, different means of communication exist between the peripheral and the CNS immune systems. 41 An inflammatory process is proposed to be involved in the pathophysiology of at least a subgroup of patients with schizophrenia.
42,43

The Effect of Inflammation on Neurotransmitters
Disturbance of dopaminergic neurotransmission has long been the primary focus of research into the neurobiology of schizophrenia, and it is clear that schizophrenia involves a dysfunction of the dopamine system. 44 However, the exact relationship between the disturbance and the disease is yet to be elucidated, and results of studies on antidopaminergic drugs are unsatisfactory.
At least two interleukins (ILs) appear to play an important role in the effects on neurotransmitter systems in schizophrenia: IL-1β, which induces rat mesencephalic progenitor cells to be converted into a dopaminergic phenotype, [45] [46] [47] and IL-6, which decreases the survival of serotonergic neurons in fetal brain. 48 Although increases in pro-inflammatory cytokines are not specific for schizophrenia and described also in other psychiatric disorders, the interaction between cytokines and neurotransmitters in certain brain regions and in particular during brain development contributes to the pathophysiology of schizophrenia. In a mouse model of viral-like infection, the number of mesencephalic dopaminergic neurons increased in the brains of fetuses after an immune response was elicited in the pregnant dams. 49 The authors proposed that the increase was likely associated with an excess of dopamine in the midbrain, a structure involved in schizophrenia in humans. 49 Latent persistent infections have been proposed to potentially cause imbalances of the immune reaction. 50 Chronic administration of interferon-α in animals, however, is associated with a reduction in the release of striatal dopamine and with anhedonia. 51 This finding points to diverse effects of inflammation on dopaminergic neurotransmission, which may play a role in chronification of schizophrenia. Anhedonia is well known to be a characteristic negative symptom in schizophrenia, and negative symptoms are often found in chronic schizophrenia.
Glutamate, the most abundant neurotransmitter in the CNS, is assumed to be a key factor in the pathophysiology of schizophrenia because of its involvement in cytokine-directed tryptophan/kynurenine metabolism, which is mediated via NMDA receptors, among others. Kynurenic acid is the only known naturally occurring NMDA receptor antagonist in the human CNS 53 and is one of three or more intermediate neuroactive products in the kynurenine pathway. In the proposed mechanism of effect in schizophrenia, a predominant type 2 immune response inhibits indoleamine 2,3-dioxygenase (IDO), which results in increased production of kynurenic acid and consequently in antagonism at NMDA receptors and a lack of glutamate neurotransmission. 54, 55 The finding that NMDA receptor antibodies are present in about 10% of unmedicated patients with acute schizophrenia supports the view that NMDA receptor antagonism plays a role in the pathology of schizophrenia. 56, 57 However, findings on the relevance of kynurenic acid in schizophrenia are inconsistent. Some studies found increased kynurenic acid levels, mainly in the CSF 58, 59 and brains of patients with schizophrenia 60, 61 and in animal models of schizophrenia, 62 whereas others found no increase in kynurenic acid levels in the peripheral blood of patients with firstepisode schizophrenia 63 or in other groups of schizophrenia patients. 64 An important caveat for many of the studies discussed in this section is that the patient samples are generally not antipsychotic naïve, and antipsychotics can potentially interfere with biomarker levels, including the metabolites of the kynurenic metabolism. [63] [64] [65] Moreover, kynurenic acid in the CSF and blood may show different concentrations in schizophrenia because CSF may represent a pathological process better than peripheral blood.
The Possible Role of Infection in Schizophrenia
Animal models have provided evidence for the role of preand perinatal infections in the later development of schizophrenia. 66, 67 For example, in animal models, offspring shows typical symptoms of schizophrenia, such as cognitive deterioration or startle reflex abnormalities, after prenatal exposure to viral agents. 68, 69 Evidence is available also from studies in humans after prenatal or childhood exposure to different viruses, [70] [71] [72] [73] respiratory infections, 74 genital or reproductive tract infections, 74, 75 Toxoplasma gondii, 76 and other infections. [77] [78] [79] [80] Although many studies have examined antibody titers against viruses in the sera of patients with schizophrenia, the results have been inconsistent. 81 The findings may have been unclear because studies did not control for confounding variables such as possible polyclonal immune activation or smoking and because antibody levels are affected by medication. 82 In one of our own studies, patients with schizophrenia had higher titers of various pathogens than healthy controls, a phenomenon that we termed the "infectious index." 83 Several studies indicate that immune activation during pregnancy of the mother increases the offspring's risk for developing schizophrenia. For example, animal studies have shown that high IL-6 levels in utero cause schizophrenia-like symptoms in the offspring and that these symptoms can be reversed by anti-IL-6 antibodies. 84 Also, IL-6 levels in childhood predict the later risk for schizophrenia. 85 Because of space limitations, the topic of a pro-inflammatory state in utero or early childhood as a risk factor for later development of schizophrenia cannot be discussed in detail here. An interesting example, however, is the pro-inflammatory cytokine IL-8, which has been studied in human pregnant mothers: offspring had a higher risk of developing schizophrenia if exposed prenatally to increased levels of IL-8. 86 Furthermore, people with schizophrenia showed decreased brain volume, ie, lower volumes of the right posterior cingulum and left entorhinal cortex and higher volumes of the ventricles, after prenatal exposure to higher maternal IL-8 levels (measured in assays from archived prenatal sera). 87 Because schizophrenia is a disorder of late adolescence and early adulthood, the possible mechanism of the associations between early life infection and adult schizophrenia has to be addressed. Many studies show that early infection or immune activation influences several neurodevelopmental processes, including dopaminergic and glutamatergic neurotransmission in animal models. 46, 88 In humans, studies on certain infections 89 and a cohort study of bacterial infections 74 are examples that underline this association. Increased levels of cytokines or C-reactive protein in childhood indicate an increased risk for schizophrenia. 90 Infection in later life has also been linked to an increased risk for schizophrenia. For example, a largescale, 30-year epidemiological register study in Denmark found that autoimmune disorders and severe infections requiring hospitalization increased the risk of schizophrenia and schizophrenia spectrum disorders, particularly in patients with both risk factors. 91 Interestingly, this study did not find evidence that infections of the parents, including intrauterine infections, were definite risk factors for the development of schizophrenia in the offspring. 91, 92 However, despite the large scale of the study, the authors determined that the study did not have very high sensitivity, and the identified risk factors were therefore only the "tip of an iceberg."
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Inflammation and Volume Loss in the CNS-Findings from Imaging Studies
Neuroimaging and neuropathological studies have not found large inflammatory changes in schizophrenia. However, they have shown reductions in CNS volume in first-episode schizophrenia and progressive loss in the course of the disease. [93] [94] [95] [96] One study found that the volume loss in schizophrenia is associated with an increased genetic risk for greater production of IL-1β, an immune marker 97 ; as mentioned above, maternal IL-8 levels were found to be related to CNS volume. 87 Neuroinflammation can be measured by PET with ligands for the translocator protein (PK 11195, DAA1106), a receptor that is expressed by activated microglia and upregulated in inflammation. Radiolabeled PK11195 can therefore be used in PET to estimate microglial activation in the CNS. 98 Studies have found greater binding of PK11195 in schizophrenia, indicating neuroinflammation. 99, 100 In addition, another study found that positive symptoms of schizophrenia correlated with expression of the PET-activation marker DAA1106 and that duration of the disease correlated with expression of the microglial activation marker DAA1106. 101 It has to be mentioned, however, that the results of PET studies in schizophrenia are inconsistent, 102 as is the interpretation of the data. 103 The stage of schizophrenia (eg, first episode vs chronic), medication, and additional interfering variables may also play a role in the conflicting results.
Anti-inflammatory Treatment in Schizophrenia
The finding that anti-inflammatory medication is beneficial in schizophrenia provides perhaps the most convincing evidence that inflammation is involved in schizophrenia. A detailed overview on the efficacy of anti-inflammatory treatment in schizophrenia has been published elsewhere. 104 This summary focuses on cyclooxygenase (COX) inhibitors. The most broadly studied COX inhibitor is the COX-2 inhibitor celecoxib. A 6-week prospective, randomized, double-blind study in patients with an acute exacerbation of schizophrenia compared celecoxib as an add-on to risperidone with risperidone and a placebo add-on. 105 Outcome was significantly better in the celecoxib add-on group (n = 25) than in the group receiving only the antipsychotic (n = 25), 105 whereby the effects on cognition were especially pronounced. 106 Data from this study were pooled with data from another 6-week study of risperidone and celecoxib add-on, and the resulting group of n = 90 cases was analyzed. The analysis found that patients who had been ill for 2 years or less benefited from the celecoxib add-on, whereas patients with longer disease duration did not differ from the placebo add-on group (see Figure 2) . This finding indicates that treatment of schizophrenia patients with a COX-2 inhibitor is most beneficial in the initial period of the disease process. Support for this hypothesis is provided by a study that found no benefit of celecoxib in chronic schizophrenia. 107 To further test this hypothesis, my group studied celecoxib as an add-on to amisulpride in first-manifestation schizophrenia. 108 We found positive effects of celecoxib add-on treatment on the Positive and Negative Syndrome Scale (PANSS) positive, negative, and total scores and on the general psychopathology score. 108, 109 A caveat with regard to the COX-2 inhibitors is the increased risk of adverse cardiovascular events.
Acetylsalicylic acid (ASA), another anti-inflammatory agent, has also shown positive effects in schizophrenia spectrum disorders. 110 A meta-analysis of five double-blind studies of nonsteroidal anti-inflammatory drugs in schizophrenia (four studies of celecoxib and one of ASA) found significant effects of the drugs on overall symptoms and both positive and negative symptoms. 111 However, a meta-analysis of eight studies (six of celecoxib and two of ASA) in schizophrenia found significant effects in first-episode but not chronic patients and in inpatients but not outpatients. 112 The studies described above indicate that the efficacy of anti-inflammatory treatment is associated with the disease stage, ie, such treatment shows less efficacy in chronic schizophrenia (which may be related to the degree of neuroprogression). The negative impact of chronification on the outcome of schizophrenia in general is well known from studies of first-and second-generation antipsychotics. Nevertheless, so far anti-inflammatory treatment has been evaluated in schizophrenia only in short-term studies lasting a few Fig. 2 . Comparison of disease duration on the effects of celecoxib add-on therapy to risperidone. Patients with disease duration <2 years and celecoxib treatment had a better outcome than patients with a disease duration >2 years and placebo and both groups of patients with a disease duration of more than 2 years (results not statistically significant). Adapted from Ref.
weeks at the most. Of relevance in this context is that short-term anti-inflammatory treatment also shows only weak effects in chronic inflammatory diseases. Longer term anti-inflammatory treatment may have more positive effects in chronic schizophrenia. 113 Possible predictors for a better treatment response to anti-inflammatory treatment require further study. All the studies on the link between inflammation and clinical outcomes in psychosis found that higher inflammation is associated with poorer response to antipsychotics. [114] [115] [116] [117] Whether high levels of inflammation predict a better outcome to anti-inflammatory treatment-as could be shown in major depression for anti-TNF treatment and for celecoxib 118, 119 -has to be proven. To date, no immune-related prediction markers have been identified for anti-inflammatory treatment.
Of importance in this context, however, is that several nonsteroidal anti-inflammatory drugs, such as COX-2 inhibitors, probably also have nonimmunemediated effects, 120 although their effects are most likely due to their common denominator, ie, their effects on inflammation. More convincing evidence for a pathophysiological role of inflammation in schizophrenia would be provided by monoclonal antibodies against targets in the immune system because these antibodies do not have any other direct or indirect effects on neurotransmitters.
Other Immune-related Substances in Schizophrenia As described above, microglia activation is involved in inflammatory processes in the CNS. The antibiotic minocycline crosses the blood-brain barrier is known to inhibit microglia activation and, consequently, is of interest in schizophrenia. In animal models of schizophrenia, it has been shown to improve cognition. 121 In patients with schizophrenia, double-blind, placebo-controlled addon studies also found positive effects of minocycline on negative and cognitive symptoms. 122, 123 Case reports have described positive effects of minocycline on the overall symptom spectrum in schizophrenia. 124 Substances with anti-inflammatory and other effects, including acetylcysteine and omega-3 fatty acids, have been found to have some beneficial effects in schizophrenia. 104 The cytokine interferon-gamma (IFN-γ) stimulates the monocytic type 1 immune response and has shown encouraging, although preliminary, results in schizophrenia. 125 Treatment with IFN-γ requires careful monitoring of side effects, including unwanted immune effects.
Because the immune system and cytokines in particular appear to be involved in schizophrenia, monoclonal antibodies against pro-inflammatory cytokines may be expected to show positive effects in schizophrenia. 126 The data from the few studies performed to date indicate that treatment with monoclonal antibodies is feasible and may show efficacy, but further research is needed.
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Conclusion
For a long time, little attention was paid to the potential involvement of an immunological process and consequent inflammation in the pathogenesis of schizophrenia. However, the evidence base for a range of relevant topics is growing, including the role of pro-inflammatory cytokines, the pronounced effects of pro-and anti-inflammatory cytokines on tryptophan/kynurenine metabolism; the effects of cytokines on glutamatergic neurotransmission; the results of imaging studies; the role of genetics; and the beneficial effects of anti-inflammatory drugs in schizophrenia. Despite this growing evidence, one must remember that immunological research is susceptible to interference from a range of factors, including medication, smoking, stress, and sleep. These factors cannot always be controlled, as can be seen from the example of stress: according to the vulnerability-stress-inflammation model, stress is not only a sine qua noncondition in schizophrenia but is also a confounding factor in studies of the immune response and inflammatory processes. The same applies to neuroimaging studies, ie, volume loss might be caused by pathological processes other than inflammatory ones.
Schizophrenia is hypothesized to be a syndrome with different underlying pathological processes. The same is true for inflammation, which has various stages and processes, ranging from acute to chronic and can also be an autoimmune process. Further research is needed to clarify the immune system's role in schizophrenia, in particular the relationship between inflammatory markers in the blood and CSF on the one hand and CNS volume loss on the other and also the relevance of different stages of inflammation for the disease. Nevertheless, recent findings, including the positive results of treatment studies, are encouraging and support continued research in this fascinating field.
